December 05, 2025

Long-Term Survival With Stereotactic Ablative Radiotherapy vs Surgery for Early-Stage NSCLC

With 10 years of follow-up, no significant difference in survival rates was reported between patients who were treated with stereotactic ablative radiotherapy (SABR) or video-assisted thoracoscopic su...

The ASCO Post

December 05, 2025

Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC

In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizuma...

The ASCO Post

December 04, 2025

Why Patients Who Need a Lung Transplant Are Often Referred Too Late

A lung transplant expert explains why many doctors wait too long to get their patients onto a transplant waiting list.

Keck Medicine of USC

November 19, 2025

Lung Cancer Treatment Evolutions Include Surgical Innovation and Molecular Targeted Therapy

Lung cancer survival rates have approximately doubled over the past two decades — a remarkable achievement driven by convergent advances in early detection, surgical technique and molecular oncology.

Baptist Health South Florida

November 19, 2025

Project ASCENT: Advancing Lung Cancer Screening in Hispanic Populations

Lung cancer remains the leading cause of cancer mortality in the United States, surpassing the combined deaths of breast, colon and prostate cancers.

Baptist Health South Florida

November 14, 2025

SABR May Be Comparable to Surgery for Early-Stage NSCLC

Stereotactic ablative radiation therapy (SABR) was found to be noninferior to surgical resection in terms of overall survival for patients with early-stage non–small cell lung cancer (NSCLC), accordin...

The ASCO Post

November 11, 2025

Local Consolidative Therapy Enhances Outcomes With Osimertinib in EGFR-Mutant NSCLC

Osimertinib in combination with local consolidative therapy of radiation and/or surgery led to a significant extension of progression-free survival for patients with EGFR-mutant metastatic non–small c...

The ASCO Post

November 11, 2025

Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib/Chemotherapy in EGFR-Positive NSCLC

The combination of osimertinib plus chemotherapy led to a median overall survival of 47.5 months compared with 37.6 months with osimertinib monotherapy in patients with EGFR-mutated advanced non–small...

The ASCO Post

November 10, 2025

Long-Term Safety and Management of Adverse Events Associated With Lorlatinib in ALK-Positive Metastatic NSCLC: A Fictional Case Study

Explore how lorlatinib transformed treatment outcomes for a patient with ALK-positive metastatic NSCLC while highlighting the importance of effective management strategies.

JADPRO